Azenta Beats Q3 Estimates, Raises Full-Year Revenue and Multiomics Outlook
AZTA sits 90% above its 52-week low of $15.93.
Summary
Azenta reported Q3 adjusted EPS of $0.16, beating estimates by 45%, and raised full-year revenue guidance. The B Medical Systems sale closed, and the company repurchased $50 million in shares.
Updates
· SEC 10-Q — The 10-Q reports Q3 net income of $2.5M, nine-month net loss of $173.8M, and completion of the B Medical Systems sale on July 1, 2026 for $63.0M.
· Reuters — Adjusted EBITDA guidance is $59M-$62M for FY26.
Key Events · Earnings and Guidance · AZTA
-
Q3 Earnings Beat
Revenue of $161M (up 12% YoY, 9% organic) and non-GAAP diluted EPS of $0.16 beat consensus by 45%. Adjusted EBITDA was $18.5M with an 11.4% margin.
-
Full-Year Guidance Raised
Revenue guidance increased to $613–$618M from $603–$621M. Multiomics organic revenue outlook improved to down 1% to flat from down mid-single-digits.
-
B Medical Systems Sale Closed
The sale closed on July 1, 2026, with a $28M deposit received. The business is now reported as discontinued operations, removing a drag on earnings.
-
Share Repurchase Progress
Under the $250M repurchase program, 2.3M shares have been bought for $50M. All repurchased shares have been retired.
Analysis · AZTA · Technology
Azenta delivered a strong Q3, with adjusted EPS of $0.16 beating consensus by 45% and revenue up 12% year-over-year. The company raised its full-year revenue guidance and improved its Multiomics outlook, signaling that its turnaround is gaining traction. The B Medical Systems sale closed on July 1, removing a major overhang, and the balance sheet remains solid with $529 million in cash and securities. Against a backdrop of a recent $149 million goodwill impairment and a challenged market, these results provide concrete evidence of operational improvement.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1059 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZTA was trading at $30.25 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $15.93 to $41.73. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.